Breaking barriers to gene therapies for childhood rare diseases
The majority of known rare genetic diseases affect children, and gene therapies could help them…
The majority of known rare genetic diseases affect children, and gene therapies could help them…
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO…
The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s…
The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business…
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the…
Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder…
The development of longevity treatments is hampered by a lack of biomarkers and validated drug…
By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S.…
Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing…
The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael…
Food waste impacts the whole of society, including the field of alternative protein. Nick Cooney,…
Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could…